282 related articles for article (PubMed ID: 28559028)
1. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
3. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
[TBL] [Abstract][Full Text] [Related]
4. External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC/UICC staging system: a retrospective cohort study.
OuYang PY; You KY; Zhang LN; Xiao Y; Zhang XM; Xie FY
Cancer Commun (Lond); 2018 Sep; 38(1):55. PubMed ID: 30176932
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
6. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
7. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy.
He S; Wu YL; Gao Y; He D; Huang Y
Cancer Med; 2023 May; 12(9):10536-10552. PubMed ID: 37062057
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
Wang C; Tang X; Wang J; Song J; Xu Y
Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
[TBL] [Abstract][Full Text] [Related]
11. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
12. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial.
Kitpanit S; Jittapiromsak N; Sriyook A; Prayongrat A; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
Jpn J Clin Oncol; 2019 Dec; 49(12):1100-1113. PubMed ID: 31334768
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
Pan JJ; Ng WT; Zong JF; Lee SW; Choi HC; Chan LL; Lin SJ; Guo QJ; Sze HC; Chen YB; Xiao YP; Kan WK; O'Sullivan B; Xu W; Le QT; Glastonbury CM; Colevas AD; Weber RS; Lydiatt W; Shah JP; Lee AW
Cancer; 2016 Nov; 122(21):3307-3315. PubMed ID: 27434142
[TBL] [Abstract][Full Text] [Related]
14. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract][Full Text] [Related]
15. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
17. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Luo WJ; Zou WQ; Liang SB; Chen L; Zhou GQ; Peng H; Li WF; Liu X; Sun Y; Lin AH; Ma J; Mao YP
Radiother Oncol; 2021 Feb; 155():56-64. PubMed ID: 33039423
[TBL] [Abstract][Full Text] [Related]
18. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma.
OuYang PY; Zhang LN; Xiao Y; Lan XW; Zhang XM; Ma J; Xie FY
Oral Oncol; 2017 Apr; 67():37-45. PubMed ID: 28351579
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
20. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
